Investment Thesis
CME Group demonstrates exceptional financial health with industry-leading profitability metrics (62.5% net margin, 64.9% operating margin) and strong cash generation (4.2B free cash flow, 64.3% FCF margin). The company's capital-light business model, zero debt-to-equity ratio, and consistent revenue growth (+6.4% YoY) position it as a high-quality financial infrastructure provider with substantial competitive moats.
CME Strengths
- Exceptional profitability with 62.5% net margin and 64.9% operating margin indicating pricing power and operational excellence
- Fortress balance sheet with zero leverage (0.00x debt/equity) and 4.4B in cash providing financial flexibility
- High-quality cash generation with 4.2B free cash flow (64.3% FCF margin) supporting capital allocation flexibility
- Strong revenue growth (+6.4% YoY) with net income growth of 1.3% YoY despite margin compression, showing resilience
- Capital-efficient business model with minimal capex (83.5M) relative to operating cash flow (4.3B)
CME Risks
- Tight current ratio (1.03x) suggests limited short-term liquidity cushion despite strong cash generation
- Net income growth (1.3% YoY) lags revenue growth (6.4% YoY), indicating potential margin compression or operational headwinds
- High leverage of long-term assets (198.4B total assets vs 28.7B equity) concentrated in derivative clearing operations creates systemic risk exposure
- ROA of only 2.1% despite high profitability suggests significant asset base may not be generating proportional returns
- Heavily regulated industry subject to regulatory changes affecting clearing operations and market structure
Key Metrics to Watch
- Operating margin sustainability (current 64.9%)
- Free cash flow generation and capital allocation decisions
- Revenue growth rates by business segment (derivatives clearing vs listed products)
- Regulatory changes impacting clearing house operations
- Current ratio improvement to strengthen liquidity position
CME Financial Metrics
CME Profitability Ratios
CME Balance Sheet & Liquidity
CME 5-Year Financial Trend
5-Year Trend Summary: CME GROUP INC.'s revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $8.86 reflects profitable operations.
CME Growth Metrics (YoY)
CME Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.5B | $908.0M | $2.49 |
| Q2 2025 | $1.5B | $883.2M | $2.42 |
| Q1 2025 | $1.5B | $855.2M | $2.35 |
| Q3 2024 | $1.3B | $750.2M | $2.06 |
| Q2 2024 | $1.4B | $777.6M | $2.14 |
| Q1 2024 | $1.4B | $855.2M | $2.35 |
| Q3 2023 | $1.2B | $679.6M | $1.87 |
| Q2 2023 | $1.2B | $662.5M | $1.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CME Capital Allocation
CME SEC Filings
Access official SEC EDGAR filings for CME GROUP INC. (CIK: 0001156375)